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Abstract
Background: Lower urinary tract symptoms (LUTS) are associated with great emotional costs to individuals and
substantial economic costs to society. This study seeks to evaluate the effect of a new natural compound
“Tradamixina plus Serenoa Repens” in order to improve lower urinary tract symptoms.
Methods: 100 patients (≥45years) who had had LUTS/BPH for >6 mo at screening and with IPSS -The international
Prostate symptom scores- ≥13 and maximum urinary flow rate (Qmax) ≥4 to ≤15 ml/s. were recruited. The compound
“Tradamixina plus Serenoa Repens” (80 mg of Alga Ecklonia Bicyclis, 100 mg of Tribulus Terrestris and 100 mg of
D-Glucosamine and N-Acetyl-D-Glucosamine plus 320 mg of Serenoa Repens) was administered daily for 2 months.
At visit and after 60 days of treatment patients were evaluated by means of detailed medical urological history, clinical
examination, laboratory investigations (total PSA), and instrumental examination like urolfowmetry. Efficacy measures
included IPSS-International Prostate Sympto, BPH Impact Index (BII), Quality-of-Life (QoL) Index. Measures were assessed
at baseline and end point (12 wk or end of therapy) and also at screening, 1 and 4 wk for IPSS, and 4 wk for BII.
Statistical significance was interpreted only if the results of the preceding analysis were significant at the 0.05 level.
Results: After 2 months of treatment the change from baseline to week 12 relative to “Tradamixina plus Seronea
Repens” in total IPSS and Qol was statistically significant. Differences from baseline in BII were statistically significant
for “Tradamixina plus Seronea Repens” above all differences in BII were also significant at 4 wk (LSmean ± SE:
-0.8 ± 0.2). In the distribution of subjects over the PGI-I and CGI-I response categories were significant
for”Tradamixina plus Seronea Repens” (PGI-I: p = 0.001; CGI-I). We also observed a decrease of total PSA.
Conclusion: The daily treatment with a new compound “Tradamixina plus Serenoa Repens” for 2 months
improved the male sexual function , it improved the bother symptoms which affect the patient’s quality of life ,
improved uroflowmetric parameters, and we also observed a decrease of serum PSA level.
Background
Lower urinary tract symptoms (LUTS) are associated
with great emotional costs [1] to individuals and sub-
stantial economic costs to society [2]. The prevalence
and severity of LUTS increases with age [3], and the
progressive growth of the aged population group has
broadened the societal impact of LUTS. LUTS comprise
storage symptoms (daytime urinary frequency, nocturia,
urgency, urinary incontinence) voiding symptoms (slow
stream, splitting or spraying, intermittency, hesitancy,
straining, terminal dribble), and post micturition symp-
toms (sensation of incomplete emptying, post micturi-
tion dribble) [4] In EPIC, 62.5% of 7210 men in the five
countries surveyed reported one or more LUTS; the
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prevalence of individual LUTS in men increased with
age. A greater percentage of men reported storage
symptoms (51.3%) vs. voiding (25.7%) or post micturi-
tion (16.9%) symptoms. Nocturia, defined by the ICS as
waking one or more times to urinate during the night,
was the most commonly reported symptom (48.6% of
men); terminal dribble (14.2% of men) and sensation of
incomplete emptying (13.5% of men) were the most
commonly reported voiding and post micturition symp-
toms, respectively [5]. A large-scale multinational study
revealed that 90%of men aged 50 to 80 suffer from
potentially troublesome LUTS [3]. Questionnaire data
from 1,271 men with LUTS indicated that many men
have storage and voiding symptoms [6]. The same study
demonstrated that voiding symptoms were the most
common male LUTS, but that storage symptoms made
up four of the five most bothersome LUTS. Although
LUTS are also highly prevalent in women, their frequent
comorbidity with prostatic disease in men adds com-
plexity to the management of male LUTS [6]. Benign
prostatic hyperplasia (BPH) is a pathologic process that
contributes to, but is not the sole cause of, lower urinary
tract symptoms (LUTS) in aging men. Despite intense
research efforts in the past five decades to elucidate the
underlying etiology of prostatic growth in older men,
cause-and effect relationships have not been established.
For example, androgens are a necessary but not a clearly
causative aspect of BPH. Previously held notions that
the clinical symptoms of BPH are due simply to a mass-
related increase in urethral resistance are too simplistic.
It is now clear that a significant portion of LUTS is due
to age –related detrusor dysfunction. Bladder outlet
obstruction itself may induce a variety of neural altera-
tion in the bladder, which contributes to symptomatol-
ogy. Moreover bothersome LUTS may be seen on men
with polyuria, sleep disorders, and a variety of systemic
medical conditions unrelated to the prostate- bladder
unit. BPH is but one cause of the LUTS in aging men
commonly, and probably incorrectly, referred to as pros-
tatism. BPH is a classical age-related disease and present
in 20% of men at the age of 40 years, with progression
to 70% at the age of 60 years [7]. The clinical relevance
of this disorder is underscored by the fact that up to
50% of elderly men develop lower urinary tract symp-
toms (LUTS) due to BPH/BPE, and that transurethral
resection of the prostate remains one of the most fre-
quent interventions in elderly men, with a lifetime risk
for surgery of around 25–30% [7]. Histopathologically,
BPH is characterized by an increased number of epithe-
lial and stromal cells around the urethra with an exces-
sive nodular growth localized to the points where
ejaculatory ducts enter into the transitional or periurethral
zones of the prostate. At the cellular level, alterations
including basal cell hyperplasia (enlarged, hypertrophic
basal cells), increased stromal mass (particularly the
amount of smooth muscle cells), enhanced extracellular
matrix deposition, reduced elastic tissue, more infiltrating
lymphocytes around ducts, acinar hypertrophy and more
luminal corpora amylacea and calcifications in the form of
prostatic calculi [8]. Periurethral nodules in BPH compress
the urethra and may cause urodynamic obstruction. Such
an obstruction can lead to LUTS as well as secondary
changes that may ultimately require surgical intervention,
such as bladder hypertrophy, urinary tract infection devel-
opment of post-void residual volume, upper urinary tract
changes and urinary retention. The observed increase in
cell number may be due to epithelial and stromal prolif-
eration or to impaired programmed cell death leading to
cellular accumulation. Androgens, estrogens, stroaml,
epithelial interactions, growth factors, and neurotransmit-
ters may play a role, either singly or in combination in the
etiology of the hyperplastic process. The prostate receives
innervations from the sympathetic and the parasympa-
thetic nerve system. The sympathetic system (noradrener-
gic nerves) is responsible for expelling prostatic fluid into
the urethra during ejaculation [9], and the parasympa-
thetic system (cholinergic nerves) increases the rate of
secretion [10]. Moreover, the neuronal system has been
shown to regulate prostatic function and growth [11].
Neuronal systems with effects on the prostate include the
alpha adrenergic [12], the beta adrenergic [13] the choli-
nergic [14], the enkephalinergic [15], the peptidergic [16]
and the nitrinergic system [13]..Sympathetic signaling
pathways are important in the pathophysiology of LUTS,
as reviewed subsequently. In addition, there is increasing
evidence that sympathetic pathways may be important in
the pathogenesis of the hyperplastic growth process.
Alpha blockade, in some model systems can induce apop-
tosis [17,18]. a –adrenergic pathways can also modulate
the smooth muscle cell phenotype in the prostate[19]. All
the components of the rennin-angiotensin system are pre-
sent in prostatic tissue and may be active in BPH [20].
The alpha-1-adrenoreceptor is the prime determinant for
urethral resistance causing outflow obstruction and LUTS
[21]. Based on this observation, an important cornerstone
of medical management of LUTS due to BPH/BPE is
based on alpha-1-adrenergic-receptor (adrenoreceptor)
blockade to reduce urethral resistance. This study seeks to
evaluate the effect of a new natural compound “tradamix-
ina “ made of Alga Ecklonia Bicyclis, Tribulus Terrestris
and D-Glucosamine plus Serenoa Repens in order to
improve lower urinary tract symptoms. Seven phloro-
tannins were isolated and characterized from an edible
marine brown alga Ecklonia Bicyclis, along with three
common sterol derivatives (fucosterol, ergosterol, and cho-
lesterol) according to the comprehensive spectral analysis
of MS and NMR data. Compounds 7-phloro eckoland
,6,6′-bieckoll in phlorotannin derivatives were obtained for
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the first time with their respective high yields. Any bioac-
tive report of compound Fucodiphloroethol G was found
nowhere up to date [22]. Ecklonia bicyclis has radical sca-
venger activity 10-100 times more powerful than any
other polifenol terrestris plants, which have only 3-4 feno-
lic and rings that are commonly considered among the
most effective antioxidant molecules. Common polyphe-
nols are soluble in water also and have a relatively short
half-life introduced into the body. All phlorotannins had
antioxidant properties in vitro, especially, compounds 6,6′-
bieckol which showed significant activities compared to
the other phlorotannins [23]. In the Ecklonia bicyclis there
are molecules that are able to reduce the inflammatory
response, partially neutralizing the inflammatory damage
caused by ROS and in part by slowing the gaming lipoxy-
genase and inhibiting the formation of prostaglandin E2, a
powerful inflammatory mediator. Jung Wk [24] revealed
that Ecklonia bicyclis inhibits LPS-induced NO and PGE2
production in a concentration-dependent manner and
inhibits inducible iNOS and COX-2 in BV2 microglia
without significant cytotoxicity. Ecklonia bicyclis treatment
significantly reduced NF-kB translocation and DNA-bind-
ing in LPS-stimulated BV2 microglia. This effect was
mediated through the inhibition of the degradation of the
inhibitor kappaB and by inhibition of the mitogen-acti-
vated protein kinase (MAPK) phosphorylation, at least in
part by inhibiting the generation of reactive oxygen spe-
cies. This data also indicate that Ecklonia bicyclis extracts
exert anti-inflammatory effects by suppressing proinflam-
matory cytokines. Collectively, these results suggest that
Ecklonia bicyclis suppresses the induction of cytokines by
LPS, as well as iNOS and COX-2 expression, by blocking
NF-kappaB and MAPK activation. These findings provide
mechanistic insights into the anti-inflammatory and neu-
roprotective actions of Ecklonia bicyclis in BV2 microglia
[24]. Won -Kyo Jung[25] revealed that also only dieckol
suppresses LPS-induced production of nitric oxide (NO)
and prostaglandin E2 (PGE2) and expression of inducible
nitric oxide synthase (iNOS) and cyclooxygenase-2
(COX-2) in a dose-dependent manner, without causing
cytotoxicity. It also significantly reduced the generation of
proinflammatory cytokines, such as interleukin (IL)-1b
and tumor necrosis factor (TNF)-a. Moreover, dieckol sig-
nificantly reduced LPS-induced nuclear factor B (NF-B)
and p38 mitogen-activated protein kinases (MAPKs) acti-
vation, as well as reactive oxygen species (ROS) produc-
tion. Taken together, the inhibition of LPS-induced NO
and PGE2 production might be due to the suppression of
NF-B and p38 MAPK signal pathway and, at least in
part, by inhibiting the generation of ROS. (25) S.-K. Kim
revealed extracts reduced the concentrations of IL-4 and
IL-5 by 66% and 84%, respectively, and resulted in a 73%
reduction in the secretion of TNF-a . Ecklonia bicyclis
extracts enhanced IFN-g production, but not to a
significant degree [26]. The protodioscin is a steroidal
saponin, which is about 45% of the extract obtained from
aerial parts of Tribulus Terrestris. Its particular steroidal
structure has an androgen-mimetic action, binding and
activating the receptor of testosterone. So this substance is
able to increase the endogenous production of testoster-
one, dihydrotestosterone, a hormone luteinizing hormone
(LH), dehydroepiandrosterone (DHEA) and dehydroepian-
drosterone sulfate (DHEA-S). Because of these effects in
experimental animals there is an increase in spermatogen-
esis and the frequency of matches. In the rabbit in particu-
lar it has been shown that the compound stimulates the
release of nitric oxide (NO) by vascular endothelium of
the corpora cavernosa thereby having a pro-erectile effect.
The mechanism behind this effect appears to involve the
pathway of steroid hormones. Although in humans proto-
dioscin is used for the treatment of erectile dysfunction
[27,28]. In a placebo-controlled study on a group of young
volunteers serum levels of testosterone, androstenedione
and luteinizing hormone were detected after administra-
tion of Tribulus Terrestris at doses of 10 and 20 mg/kg.
After 4 weeks of treatment, these values were similar to
those of untreated [29]. Biovis contains polymers of d-glu-
cosamine and n-acetyl-d-glucosamine that act on both the
non-adrenergic and non-colinergic system (NANC) and
on the endothelial cell system as a strong nitric oxide
synthetase (NOS) stimulator [30]. Serenoa Repens has
been approved in France and Germany for treatment of
BPH [31]. The mechanism of action of Serenoa Repens
has been investigated in several in vitro or indirect in vivo
studies and has not been definitively defined. The mechan-
ism may include alteration of cholesterol metabolism, anti-
oestrogenic, anti-androgenic (including 5a-reductase inhi-
bitor activity), anti-inflammatory effects, and a decrease in
available sex hormone binding globuline [32,34].
Methods
An observational study was conducted from May 2011
to May 2012, at our Department of Urology. We
enrolled 100 patients. Eligible men were ≥45 yrs. of age
who had had LUTS/BPH for >6 mo at screening and
with IPSS (The international Prostate symptom scores)
≥13 and maximum urinary flow rate (Qmax) ≥4 to ≤15
ml/s. Exclusion criteria were: drug assumption :a-
blocker , Serenoa Repens , dutasteride, finasteride;
hyper- and hypothyroidism, neurogenic syndrome (mul-
tiple sclerosis, multiple atrophy, Parkinson’s disease,
tumors, stroke, disk disease, spinal cord disorders, poly-
neuropathy, uraemia), lower pelvic surgery (oncological
pelvic surgery, lower urinary and genital tract surgery),
prostate cancer. The compound “Tradamixina plus
Serenoa Repens” (80 mg of Alga Ecklonia Bicyclis, 100 mg
of Tribulus Terrestris and 100 mg of D-Glucosamine and
N-Acetyl-D-Glucosamine plus 320 mg of Serenoa Repens)
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was administered daily for two months. At visit patients
were evaluated by means of detailed medical urological
history, clinical examination, laboratory investigations
(total PSA), and instrumental examination like uroflowme-
try. Efficacy measures included IPSS-International Prostate
Symptom Scores (primary measure), BPH Impact Index
(BII), and week 1 IPSS (mIPSS) questions beginning with
‘‘Since your last visit.’’ IPSS storage and voiding subscores,
nocturia question (question 7), and IPSS Quality-of-Life
(QoL) Index were also assessed. Measures were assessed
at baseline and end point (12 wk or end of therapy) and
also at screening, 1 and 4 wk for IPSS, and 4 wk for BII.
The Patient and Clinician Global Impression of Improve-
ment (PGI-I and CGI-I, respectively) instruments and the
subject-rated Treatment Satisfaction Scale–BPH (TSS-
BPH) [22], evaluated from 0% (greater) to 100% (lower)
satisfaction, were administered at end point. Uroflowmetry
was performed using standard calibrated devices at the
screening, baseline, and end point visits. Valid Qmax mea-
surements required prevoid total bladder volume (assessed
by ultrasound) of ≥150 to ≤550 ml and voided volume
(Vvoid) of ≥125 ml. Bladder capacity was calculated post
hoc as the sum of Vvoid and postvoid residual (PVR)
volume. Safety was evaluated based on subject-reported
adverse events (AE), PVR, clinical laboratory parameters
(total PSA). The primary efficacy objective was evaluating
the change in total IPSS from baseline to end point. Effi-
cacy was analysed in all subjects. At last continuous effi-
cacy measures, uroflowmetry, and PVR were evaluated as
a change from baseline to week 12/last-observation car-
ried-forward end point. All other efficacy analyses (includ-
ing all tradamixina results) were assessed at the 0.05
significance level without adjustment for multiplicity.
A fixed-sequence testing procedure was implemented to
control type I error in analyses of primary and key second-
ary outcomes for “Tradamixina plus Serenoa Repens”
using the following pre-specified order: total IPSS at end
point, total IPSS after 4 wk, BII at end point, mIPSS after
1 wk, and BII after 4 wk. Statistical significance was inter-
preted only if results of the preceding analysis were signifi-
cant at the 0.05 level. Results were presented independent
of the fixed sequence, as all end points tested under this
procedure achieved statistical significance. All other effi-
cacy analyses were assessed at the 0.05 significance level
without adjustment for multiplicity. PGI-I- Patient Global
Impression of Improvement- was analysed using the
Cochran –Mantel-Haenszel test adjusted for baseline
LUTS severity .Changes from baseline to end of therapy in
Qmax, PVR, and clinical laboratory parameters were ana-
lysed using a ranked analysis of variance (ANOVA) with a
term for treatment group. Treatment group differences for
average urinary flow rate (Qave), Vvoid, and bladder capa-
city were performed as post hoc analyses.
Results and discussion
Mean age was 64 yrs. of age (10.2% ±75 yr of age). At
randomisation, IPSS was ≥20 in 30% of subjects, and
Qmax was <10 ml/s in 54%. The change from baseline to
week 12 relative to “Tradamixina plus seronea Repens” in
total IPSS was statistically significant p = 0.001 (Table 1).
Least squares mean (LSmean) plus or minus standard
error (SE) differences in IPSS were significant for “Trada-
mixina plus Serenoa Repens” at 1 wk (mIPSS: -1.5 ± 0.5;
p = 0.003 ) and 4 wk (-2.2 ± 0.6; p < 0.001 ). Changes in
IPSS subscores and nocturia are shown in table 1. Differ-
ences from baseline in BII were statistically significant for
“Tradamixina plus Seronea Repens” ( p = 0.003), above
all differences in BII were also significant at 4 wk
(LSmean ± SE: -0.8 ± 0.2;p < 0.001 ). For the IPSS QoL
Index, significant improvements at 12 wk were reported
(p = 0.022).(Table 2). The TSSBPH overall satisfaction
score at end point was significantly low (indicating higher
satisfaction) ( p = 0.005).In the distribution of subjects
over the PGI-I and CGI-I response categories were signif-
icant for “Tradamixina plus Seronea Repens” (PGI-I: p =
0.001; CGI-I: p = 0.004). More subjects and their clini-
cians perceived improvements in LUTS at end point .
Improvements in Qmax were significantly great (p =
0.009) (Table 3). For PVR, mean reductions from were
observed with “Tradamixina plus Serenoa Repens”, but
were not statistically significant. We also observed a
decrease of total PSA (Table 4). “Tradamixina plus Ser-
enoa Repens” improved total IPSS score and PGI-I and
CGI-I scores because the Ecklonia bicyclis with its anti-
inflammatory action and antioxidant effects, suppress
LPS-induced production of nitric oxide (NO) and prosta-
glandin E2 (PGE2) and expression of inducible nitric
oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) in
a dose-dependent manner, without causing cytotoxicity.
It also significantly reduced the generation of proinflam-
matory cytokines, such as interleukin (IL)-1b and tumor
Table 1 International prostate symptom score (IPSS)
total,storage and voiding subscores and nocturia
question (IPSS question 7).
IPSS total:
Change from baseline ,LS mean ±SE -6,3±0,5 p= 0.001
Storage subscore 1
Change from baseline ,LS mean ±SE -2,2±0,2 p= 0.055
Voiding subscore2
Change from baseline ,LS mean ±SE -4,1± 0.3 p< 0,001
Nocturia question3
Change from baseline ,LS mean ±SE -0,5± 0.13 p= 0,080
1) IPSS question: 2+4+7
2) IPSS question: 1+3+5+6
3) IPSS question:7
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necrosis factor (TNF)-a. Moreover, dieckol significantly
reduced LPS-induced nuclear factor B (NF-B) and p38
mitogen-activated protein kinases (MAPKs) activation, as
well as reactive oxygen species (ROS) production [25]. It
improved the bother symptoms. BPH is associated with
changes of innervations, and biological mediator produc-
tion and release in the central zone of the prostate [35].
In particular, there is a decrease of nerves of the
enkephalinergic [36] and nitrinergic systems [37,38] both
mediating smooth muscle cell relaxation [37]. Compared
to normal tissue, nNOS expression has been observed to
decrease in the transitional zone of BPH tissue. On the
other hand, inducible NOS (iNOS), produced after sti-
mulation by immune and inflammatory cytokines and
free radicals, has been reported to increase selectively in
the stroma of patients suffering from BPH [36]. This
observation is probably due to increased proinflamma-
tory conditions in BPH. The importance of the NOS sys-
tem for the prostate stroma is further supported by
experiments with constitutive active NOS dependent
guanylylcyclases. cGMP analogues have been shown to
activate the Proteinkinase G II and to inhibit proliferation
of human smooth muscle cells in vitro [37]. Two
enzymes, the neuronal (NOS-I) and the endothelial
(NOS-III) isoforms, are Ca2_-dependent and constitu-
tively expressed.The third enzyme is an inducible Ca2_-
independent isoform (NOS-II), expressed after stimula-
tion with Escherichia coli lipopolysaccharide (LPS) and/
or different cytokines, such as interferon-g (IFNg), inter-
leukin-1, or tumor necrosis factor- NOS-II induction
occurs at the transcriptional level and is mediated by the
early activation of some nuclear transcriptional factors,
including NFkB [38]. A large body of experimental evi-
dence suggests that physiological levels of NO, similar to
those produced by the basal activity of NOS-I or NOS-
III, prevent induction of NOS-II mRNA expression
through the suppression of NFkB activation [39,40]. As a
consequence, NOS-II gene expression takes place after
LPS/cytokine stimulation, provided that the NOS-I- or
NOS-III-generated NO is reduced below a threshold
value in a short time [41]. A recent report [42,43] shows
that NOS-II inducers (e.g. LPS and IFNg) consistently eli-
cit a rapid inactivation of NOS-I by tyrosine phosphoryla-
tion, an event leading to a decrease of basal NO levels.
A recent study [44] reports that inhibition of NOS-I can
be achieved via activation of cytosolic phospholipase A2
(cPLA2), a large molecular mass member of the family of
PLA2 enzymes. The activities of NOS-I and cPLA2 are
both regulated by increases in the intracellular concentra-
tion of free Ca2 ([Ca2]i). Not surprisingly, enhancing the
[Ca2]i caused a parallel increase in both activities and
accumulation of respective products, NO and arachidonic
acid (AA). Inducible nitric oxide synthase (iNOS) is
expressed in a variety of cell types, in particular in inflam-
matory cells, in response to diverse pro-inflammatory
stimuli. This process requires critical levels of arachidonic
Table 2 International Prostate Symptom Score Quality of
Life Index, Treatment Satisfaction scale, and Patient or
Clinician Global Impression of Improvement Scores at
12 wks. compared to baseline
IPSS total Qol index




Very much better 58
Much better 35
A little better 5
No change 2
A little worse 0
Much worse 0
Very much worse 0
CGI-I no.
Very much better 41
Much better 30
A little better 15
No change 14
A little worse 0
Much worse 0
Very much worse 0
















Qmax = maximum flow rate; Qave = average flow rate; Vvoid = voided
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acid (AA), generated by constitutive phospholipase
A2 (PLA2), promoting tyrosine kinase-dependent phos-
phorylation, and inhibition, of constitutive NOS. Lowering
basal NO levels is indeed critical for the activation of
NF-B, and thus for the expression of genes (e.g. iNOS)
regulated by this transcription factor. It is interesting to
note that NO and AA, two small lipid soluble molecules,
rapidly cross the plasma membrane thereby allowing the
triggering of the above responses in distal cells. That is,
constitutive NO might inhibit NF-B activity in the same
cells (e.g. astrocytes) in which it is generated, as well as in
other cells that do not express constitutive NOS (e.g.
microglia). NO from cells unable to respond to pro-
inflammatory stimuli (e.g. neurons) will also contribute to
these effects. Along the same line, AA released by pro-
inflammatory molecules in specific cell types (e.g. astro-
cytes) might suppress constitutive NOS activity in the
same cells as well as in other cells (e.g. neurons). Thus,
AA produced at the very early stages of the inflammatory
response is a likely critical signal switching the regulation
of the “NO tone” from physiological (i.e. mediated by con-
stitutive NOS) to pathological (i.e. mediated by iNOS).
This second phase of the inflammatory response is often
accompanied by the onset of deleterious effects in the tis-
sue in which a critical role is played by iNOS-derived NO
(directly or indirectly, i.e. via formation of peroxynitrite) as
well as by products of the AA cascade. In summary, the
relative amounts of NO and AA, released by their consti-
tutive enzymes, produce autocrine and paracrine effects
regulating the onset of an inflammatory response in
which, in addition to other factors, NO and AA are exten-
sively released by their inducible enzymes [45]. Biovis
contains polymers of d-glucosamine and n-acetyl-d-gluco-
samine that act both on the non-adrenergic and non-
colinergic system (NANC) and on the endothelial cell
system as a strong nitric oxide synthetase (NOS) stimula-
tor [46]. This explains why there is an improvement of
Qave and Qmax. In fact while a-blocker drugs facilitated
the opening of the bladder neck thanks to the presence of
alpha receptors, Tradamixina improved the NOS action
on its receptor, so for the reasons above also improved
LUTS. Serenoa Repens also has anti-inflammatory effects.
As described above, a1-adrenoceptor antagonists are com-
monly used in the treatment of men with voiding symp-
toms (urinary obstruction, pollakiuria and urinary
incontinence) secondary to BPH. Goepel et. Al. have
shown that Serenoa Repens might have a1-adrenoceptor
inhibitory properties. Serenoa Repens significantly affects
pharmacological receptors, such as the a1-adrenoceptor
and the muscarinic receptor in the lower urinary tract, to
relieve the irritative and obstructive symptoms of dysuria
due to BPH and LUTS [34]. In addition to traditionally
used medications, like a1-adrenoceptor antagonists, anti-
muscarinics, 5a-reductase inhibitors, and phytotherapy,
several new therapeutic agents, such as selective b3-adre-
noceptor agonists, are potentially useful for treating LUTS
suggestive of BPH, particularly for storage symptoms sec-
ondary to outflow obstruction [47]. Thus, the effects of
SPE on these receptors in the lower urinary tract might be
pharmacologically relevant. To date, more than 11 pla-
cebo-controlled trials and 4 active-controlled trials with
SPE in men with BPH have been conducted. Patient num-
bers were usually limited and the evaluation periods were
relatively short, so it would be difficult to evaluate the
effect of SPE and ascertain the efficacy of SPE in BPH
patients. However, some placebo-controlled studies and
comparisons to a1-blockers have recently been conducted
with relatively long-term treatments and sufficient num-
bers of patients [48-50]. BPH causes dysuria and residual
urine via a mechanical stoppage due to hypertrophy of
prostatic tissue and via a functional stoppage caused by
a1-adrenoceptor hypertonia of prostatic smooth muscle.
Previous studies have demonstrated that Serenoa Repens
had a number of pharmacological effects: 1) an antiandro-
genic effect — inhibition of 5a-reductase I and II and inhi-
bition of binding of dihydrotestosterone (DHT) to the
cytosolic androgen receptors, 2) an anti-inflammatory
effect, 3) an anti-proliferative effect, and 4) significant
binding of pharmacological receptors existing in the lower
urinary tract. In BPH there is a decreased ratio between
androgen and estrogen, and tribulus terrestris by increas-
ing total testosterone serum level restores the ratio.
Conclusion
The daily treatment with a new compound “Tradamix-
ina” (100 mg of Alga Ecklonia Bicyclis, 80 mg of Tribu-
lus Terrestris and 80 mg of D-Glucosamine and N-
Acetyl-D-Glucosamine) plus 320 mg Serenoa Repens for
two months improved the male sexual function. It
improved the bother symptoms which affect the
patient’s quality of life, improved uroflowmetric para-
meters, and we observed a decrease of serum PSA level.
These effects are due to its antioxidant, anti-aging
action, and the bother symptoms due to its anti-inflam-
matory action. Infact it neutralizes the action of ROS,
LPS, COX2, NFkb, probably also reducing the concen-
trations of TNF-a, MMP-1. The decrease of PSA is due
to the anti-inflammatory action. This result can be the
basis for future research.
List of abbreviations
AA: Arachidonic acid; AE: Adverse events; BII: BPH Impact Index; BPH: Benign
prostatic hyperplasia; CGI-I: The Clinician Global Impression of Improvement;
COX-2: Cyclooxygenase-2; cPLA2: Cytosolic phospholipase A2; DHEA:
Dehydroepiandrosterone; DHEA-S: Dehydroepiandrosterone sulfate; IL-1β:
Interleukin; iNOS: Inducible nitric oxide synthase; IPSS: International Prostate
Symptom; IPSS: International Prostate Symptom; LH: Hormone luteinizing
hormone; LUTS: Lower urinary tract symptoms; MAPKs: Mitogen-activated
protein kinases; MMP-1: Matrix metalloproteinase-1; NANC: Non-adrenergic
Iacono et al. BMC Surgery 2012, 12(Suppl 1):S22
http://www.biomedcentral.com/1471-2482/12/S1/S22










and non-colinergic system; NF-κB: Nuclear factor κB; NO: Nitric oxide; NOS:
Nitric oxide synthetase; NOS-I: Neuronal Nitric oxide synthetase isoforms I;
NOS-III: Endothelial Nitric oxide synthetase isoforms III; PGE2: Prostaglandin
E2; PGI-I: Patient Global Impression of Improvement; PGI-I: The Patient and
Clinician Global Impression of Improvement; PVR: Postvoid residual; Qave:
Urinary flow rate; QoL: Quality-of-Life; ROS: Reactive oxygen species; TNF-α:
Tumor necrosis factor; TSS-BPH: Treatment Satisfaction Scale–BPH; Vvoid:
Voided volume
Acknowledgements
This article has been published as part of BMC Surgery Volume 12 Supplement 1,
2012: Selected articles from the XXV National Congress of the Italian Society of
Geriatric Surgery. The full contents of the supplement are available online at
http://www.biomedcentral.com/bmcsurg/supplements/12/S1.
Author details
1Department of Urology – University Federico II of Naples, Via S. Pansini,
5 – 80131 Naples – Italy. 2Department of General, Geriatric, Oncologic
Surgery and Advanced Technologies,-University “Federico II” of Naples. Via
Pansini, 5 - 80131 – Naples, Italy.
Authors’ contributions
FI, DP: conception and design, interpretation of data, given final approval of
the version to be published; EI, AR, GR: acquisition of data, drafting the
manuscript, given final approval of the version to be published; BA: critical
revision, interpretation of data, given final approval of the version to be
published.
Competing interests
The authors declare that they have no competing interests.
Published: 15 November 2012
References
1. Engstrom G, Henningsohn L, Steineck G, Leppert J: Selfassessed health,
sadness and happiness in relation to the total burden of symptoms
from the lower urinary tract. BJU Int 2005, 95:810-5.
2. Hu TW, Wagner TH, Bentkover JD, et al: Estimated economic costs of
overactive bladder in the United States. Urology 2003, 61:1123-8.
3. Rosen R, Altwein J, Boyle P, et al: Lower urinary tract symptoms and male
sexual dysfunction: the Multinational Survey of the Aging Male (MSAM-
7). Eur Urol 2003, 44:637-49.
4. Irwin DE, Milsom I, Hunskaar S, et al: Population-based survey of urinary
incontinence, overactive bladder, and other lower urinary tract
symptoms in five countries: results of the EPIC study. Eur Urol 2006,
50:1306-15.
5. Abrams P, Cardozo L, Fall M, et al: The standardisation of terminology in
lower urinary tract function: report from the standardisation sub-
committee of the International Continence Society. Urology 2003,
61:37-49.
6. Peters TJ, Donovan JL, Kay HE, et al: The International Continence Society
‘‘Benign Prostatic Hyperplasia’’ Study:the bothersomeness of urinary
symptoms. J Urol 1997, 157:885-9.
7. Isaacs JT: Etiology Of Benign Prostatic Hyperplasia. Eur Urol 1994,
25(Suppl.1):6-9.
8. Bostwick DG, Cooner WH, Denis L, Jones GW, Scardino PT, Murphy GP: The
Association Of Benign Prostatic Hyperplasia And Cancer Of The Prostate.
Cancer 1992, 70:291-301.
9. Bruschini H, Schmidt RA, Tanagho EA: Neurologic Control Of Prostatic
Secretion In The Dog. Invest. Urol 1978, 15:288-290.
10. Smith ER, Lebeaux MI: The Mediation Of The Canine Prostatic Secretion
Provoked By Hypogastric Nerve Stimulation. Invest. Urol 1970, 7:313-318.
11. Burnett AL, Maguire MP, Chamness SL, Ricker DD, Takeda M, Lepor H,
Chang TS: Characterization And Localization Of Nitric Oxide Synthase In
The Human Prostate. Urology 1995, 45:435-439.
12. Higgins JR, Gosling JA: Studies On The Structure And Intrinsic Innervation
Of The Normal Human Prostate. Prostate Suppl 1989, 2:5-16.
13. Tsujii T, Azuma H, Yamaguchi T, Oshima H: A Possible Role Of Decreased
Relaxation Mediated By Beta-Adrenoceptors In Bladder Outlet
Obstruction By Benign Prostatic Hyperplasia. Br. J. Pharmacol 1992,
107:803-807.
14. Caine M, Raz S, Zeigler M: Adrenergic And Cholinergic Receptors In The
Human Prostate, Prostatic Capsule And Bladder Neck. Br. J. Urol 1975,
47:193-202.
15. Jungblut T, Aumuller G, Malek B, Melchior H: Age dependency And
Regional Distribution Of Enkephalinergic Nerves In Human Prostate. Urol.
Int 1989, 44:352-356.
16. Lange W, Unger J: Peptidergic Innervation Within The Prostate Gland
And Seminal Vesicle. Urol. Res 1990, 18:337-340.
17. Anglin Ie, Glassman Dt, Kyprianou N, et al: Induction Of Prostate Apoptosis
By Alpha1- Adrenoceptor Antagonists: Mechanistic Significance Of The
Quinazoline Component. Prostate Cancer Prostatic Dis 2002, 5:88-95.
18. Partin Jv, Anglin Ie, Kyprianou N: Quinazoline-Based Alpha
1-Adrenoceptor Antagonists Induce Prostate Cancer Cell Apoptosis Via
Tgf-Beta Signalling And I Kappa B Alpha Induction. Br J Cancer 2003,
88:1615-1621.
19. Lin Vk, Benaim Ea, Mcconnell Jd: Alpha-Blockade Downregulates Myosin
Heavy Chain Gene Expression In Human Benign Prostatic Hyperplasia.
Urology 2001, 57:170-175.
20. Dinh Dt, Frauman Ag, Sourial M, et al: Identification, Distribution, And
Expression Of Angiotensin Ii Receptors In The Normal Human Prostate
And Benign Prostatic Hyperplasia. Endocrinology 2001, 142:1349-1356.
21. Lepor H, Shapiro E: Characterization Of Alpha1 Adrenergic Receptors In
Human Benign Prostatic Hyperplasia. J. Urol 1984, 132:1226-1229.
22. Yong Li, Zhong-Ji Qian, Bomi Ryu, Sang-Hoon Lee, Moon-Moo Kim, Se-
Kwon Kim: Chemical Components And Its Antioxidant Properties In Vitro:
An Edible Marine Brown Alga, Ecklonia Cava. Bioorganic & Medicinal
Chemistry 2009, 17(5):1963-1973.
23. Li Y, Qian Zj, Ryu B, Lee Sh, Kim Mm, Kim Sk: Chemical Components And
Its Antioxidant Properties In Vitro: An Edible Marine Brown Alga,
Ecklonia Cava. Bioorg Med Chem 2009, 17(5):1963-73, Epub 2009 Jan 21.
24. Jung Wk, Ahn Yw, Lee Sh, Choi Yh, Kim Sk, Yea Ss, Choi I, Park Sg, Seo Sk,
Lee Sw, Choi Iw: Ecklonia Cava Ethanolic Extracts Inhibit
Lipopolysaccharide-Induced Cyclooxygenase-2 And Inducible Nitric
Oxide Synthase Expression In Bv2 Microglia Via The Map Kinase And Nf-
Kappab Pathways. Food Chem Toxicol 2009, 47(2):410-7, Epub 2008 Dec 11.
25. Won-Kyo Jung, Soo-Jin Heo§, You-Jin Jeon, Chang-Min Lee, Yeong-
Min Park, Hee-Guk Byun, Yung Hyun Choi, Sae-Gwang Parkδ, Il-Whan Choi:
Inhibitory Effects And Molecular Mechanism Of Dieckol Isolated From
Marine Brown Alga On Cox-2 And Inos In Microglial Cells. J. Agric. Food
Chem 2009, 57(10):4439-4446.
26. Kim S-K, et al: / Biomedicine & Pharmacotherapy. 2008, 62:289e296.
27. Gauthman K, Adaikan Pg, Prasad Rn: Aphrodisiac Properties Of Tribulus
Terrestris Extract (Protodioscin) In Normal And Castrated Rats. Life Sci
2002, 71:1385-1396.
28. Adaikan Pg, Gauthaman K, Prasad Rnv, Ng Sc: Proerectile Pharmacological
Effects Of Tribulus Terrestris Extract On The Rabbit Corpus Avernosum.
Ann Acad Med Singapore 2000, 29:22-26.
29. Neychev Vk, Mitev Vi: The Aphrodisiac Herb Tribulus Terrestris Does Not
Influence The Androgen Production In Young Men. Jethnopharmacol
2005, 101:319-323.
30. Chung H, Park Sl, Kim Sc, Sung Cw, Lee Jw: Effect Of Kp 2647tm In
Patients With Erectile Dysfunction. Chung Euro & Derma Clinic, Seoul,
Korea - Central Research Institute Of Kunpoong Bio, Korea.
31. Dreikorn K, Richter R, Ackerman R, Schroeder FH: Conservative
nonhormonal treatment of patients with benign prostatic hyperplasia.
New Developments in Biosciences 5, Prostatic Hyperplasia Berlin: Walter de
Gruyter & Co; 1989, 109±31.
32. Marwick C: Growing use of medicinal botanicals forces assessment by
drug regulators. JAMA 1995, 273, 607±9.
33. McGuire E: Detrusor response to obstruction. Department of Health and
Human Services, Rockville, MD; 1987, 221.
34. Di Silverio F, D’Eramo G, Lubrano C, Flammia GP, Sciarra A, Palma E, et al:
Evidence that Serenoa repens extract displays an antiestrogenic activity
in prostatic tissue of benign prostatichypertrophy patients. Eur. Urol
1992, 2, 309±14.
35. Chapple CR, Crowe R, Gilpin SA, Gosling J, Burnstock G: The Innervation Of
The Human Prostate Gland—The Changes Associated With Benign
Enlargement. J. Urol 1991, 146:1637-1644.
36. Caine M, Raz S, Zeigler M: Adrenergic And Cholinergic Receptors In The
Human Prostate, Prostatic Capsule And Bladder Neck. Br. J. Urol 1975,
47:193-202.
Iacono et al. BMC Surgery 2012, 12(Suppl 1):S22
http://www.biomedcentral.com/1471-2482/12/S1/S22









37. Jungblut T, Aumuller G, Malek B, Melchior H: Age dependency And
Regional Distribution Of Enkephalinergic Nerves In Human Prostate.
Urol. Int 1989, 44:352-356.
38. Takeda M, Tang R, Shapiro E, Burnett AL, Lepor H: Effects Of Nitric Oxide
On Human And Canine Prostates. Urology 1995, 45:440-446.
39. Gradini R, Realacci M, Ginepri A, Naso G, Santangelo C, Cela O, Sale P,
Berardi A, Petrangeli E, Gallucci M, Di Silverio F, Russo MA: Nitric Oxide
Synthases In Normal And Benign Hyperplastic Human Prostate:.
Immunohistochemistry And Molecular Biology. J. Pathol 1999, 189:224-229.
40. Colasanti M, Suzuki H: Trends Pharmacol. Sci 2000, 21:249-252.
41. Colasanti M, Cavalieri E, Persichini T, Mollace V, Mariotto S, Suzuki H,
Lauro GM: J. Biol. Chem 1997, 272:7582-75857.
42. Colasanti M, Persichini T, Cavalieri E, Fabrizi C, Mariotto S, Menegazzi M,
Lauro GM, Suzuki H: J. Biol. Chem 1999, 274:9915-9917.
43. Palomba L, Bianchi M, Persichini T, Magnani M, Colasanti M, Cantoni O: Free
Radic. Biol. Med 2004, 36:319-329.
44. Leslie CC: J. Biol. Chem 1997, 272:16709-16712.
45. Mariotto S, Suzuki Y, Persichini T, Colasanti M, Suzuki H, Cantoni O: Cross-
Talk Between No And Arachidonic Acid In Inflammation. Curr Med Chem
2007, 14(18):1940-4.
46. Chung H, Park Sl, Kim Sc, Sung Cw, Lee Jw: Effect Of Kp 2647tm In
Patients With Erectile Dysfunction. Chung Euro & Derma Clinic, Seoul,
Korea - Central Research Institute Of Kunpoong Bio, Korea.
47. Andersson KE: LUTS treatment: future treatment options. Neurourol
Urodyn 2007, 26:934-47.
48. Bent S, Kane C, Shinohara K, Neuhaus J, Hudes ES, Goldberg H, et al: Saw
palmetto for benign prostatichyperplasia. N Engl J Med 2006, 354:557-66.
49. Debruyne F, Koch G, Boyle P, Da Silva FC, Gillenwater JG, Hamdy FC, et al:
Comparison of a phytotherapeutic agent (Permixon) with an alpha-
blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a
1-year randomized international study. Eur Urol 2002, 41:497-506,
discussion 506-7.
50. Willetts KE, Clements MS, Champion S, Ehsman S, Eden JA: Serenoa repens
extract for benign prostate hyperplasia: a randomized controlled trial.
BJU Int 2003, 92:267-70.
doi:10.1186/1471-2482-12-S1-S22
Cite this article as: Iacono et al.: Observational study: daily treatment
with a new compound “tradamixina” plus serenoa repens for two
months improved the lower urinary tract symptoms. BMC Surgery 2012
12(Suppl 1):S22.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Iacono et al. BMC Surgery 2012, 12(Suppl 1):S22
http://www.biomedcentral.com/1471-2482/12/S1/S22
Page 8 of 8
RE
TR
AC
TE
D 
AR
TI
CL
E
